Unknown

Dataset Information

0

Model-Informed Drug Development for Everolimus Dosing Selection in Pediatric Infant Patients.


ABSTRACT: Everolimus is currently approved in Europe as an adjunctive therapy for patients aged ? 2 years with tuberous sclerosis complex (TSC)-associated treatment-refractory partial-onset seizures, based on the EXIST-3 study (NCT01713946) results. As TSC-associated seizures can also affect children aged between 6 months and 2 years, a modeling and simulation (M&S) approach was undertaken to extrapolate exposure (trough plasma concentration (Cmin )) after a dose of 6 mg/m2 and reduction in seizure frequency (RSF). A physiologically based pharmacokinetic model using Simcyp was developed to predict Cmin in adult and pediatric patients, which was then used by a population pharmacodynamic model and a linear mixed effect model to predict short-term and long-term efficacy in adults (for validation) and in children, respectively. Based on the results of the M&S study, everolimus at the dose of 6 mg/m2 is anticipated to be an efficacious treatment in children 6 months to 2 years of age (up to 77.8% RSF) with concentrations within the recommended target range.

SUBMITTER: Combes FP 

PROVIDER: S-EPMC7180003 | biostudies-literature | 2020 Apr

REPOSITORIES: biostudies-literature

altmetric image

Publications

Model-Informed Drug Development for Everolimus Dosing Selection in Pediatric Infant Patients.

Combes Francois Pierre FP   Einolf Heidi J HJ   Coello Neva N   Heimbach Tycho T   He Handan H   Grosch Kai K  

CPT: pharmacometrics & systems pharmacology 20200405 4


Everolimus is currently approved in Europe as an adjunctive therapy for patients aged ≥ 2 years with tuberous sclerosis complex (TSC)-associated treatment-refractory partial-onset seizures, based on the EXIST-3 study (NCT01713946) results. As TSC-associated seizures can also affect children aged between 6 months and 2 years, a modeling and simulation (M&S) approach was undertaken to extrapolate exposure (trough plasma concentration (C<sub>min</sub> )) after a dose of 6 mg/m<sup>2</sup> and reduc  ...[more]

Similar Datasets

| S-EPMC7940353 | biostudies-literature
| S-EPMC7862213 | biostudies-literature
| S-EPMC10725261 | biostudies-literature
| S-EPMC7839485 | biostudies-literature
| S-EPMC6820606 | biostudies-literature
| S-EPMC10787203 | biostudies-literature
| S-EPMC9300170 | biostudies-literature
| S-EPMC7894404 | biostudies-literature
| S-EPMC7689911 | biostudies-literature
| S-EPMC9962320 | biostudies-literature